Publications by authors named "Li-Lian Gan"
Article Synopsis
- Despite advancements in medicine, pancreatic ductal adenocarcinoma (PDAC) has shown little progress in treatment outcomes over the last 50 years, prompting research into new strategies using genomic data from major cancer projects.
- Utilizing the genomic datasets, researchers found that tumors with higher levels of cytotoxic T lymphocyte (CTL) activity were linked to better clinical results and identified specific genes associated with lower CTL activity.
- The study also discovered that histone deacetylase inhibitors (HDACi), particularly givinostat and dacinostat, could restore CTL sensitivity in resistant PDAC cells, suggesting a potential new therapeutic approach that combines HDAC inhibitors with CTL therapy.
Pancreatic cancer ranks high among the causes of cancer-related mortality. The prognosis of this grim condition has not improved significantly over the past 50 years, despite advancement in imaging techniques, cancer genetics and treatment modalities. Due to the relative difficulty in the early detection of pancreatic tumors, as low as 20% of patients are eligible for potentially curative surgery; moreover, chemotherapy and radiotherapy (RT) do not confer a great benefit in the overall survival of the patients.
View Article and Find Full Text PDF